@Boffin99
It's a very average evaluation of value and potential.
32% chance of success for a drug that leads single-agent efficacy and is comparable to combinations in R/R AML with a differentiated first-in-class mechanism of action in FTO inhibition.
For those with the motivation to look, there is an enormous amount of data out there supporting FTO inhibition and CPACS. For a potent example, of 4 patients who were refractory to two courses of combination antimetabolites, 3 achieved durable complete responses (75%) after a single 7-day dose of Bisantrene.
40-years later the mechanism of Ara-C resistance, and sensitivity to Bisantrene may be understood.
@hotcongo probably the company that owns the IP to the reformulation of Bisantrene with a 20-year patent life. Seriously.
Ann: Race In-person Investor Briefing Invitation Perth, page-21
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
-0.075(4.12%) |
Mkt cap ! $303.9M | |||
| Open | High | Low | Value | Volume |
| $1.84 | $1.84 | $1.74 | $371.9K | 210.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 488 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.78 | 793 | 1 |
View Market Depth
| Last trade - 16.10pm 02/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |